Literature DB >> 10906769

Performance evaluation of a new chemiluminescent assay for prostate specific antigen.

A Dasgupta1, A Wells, P Datta.   

Abstract

Prostate specific antigen (PSA) is a glycoprotein found in the epithelial cells of the prostatic duct and acini. PSA is elevated in all four stages of prostate cancer as well as in benign prostatic hypertrophy. We evaluated a new chemiluminescent assay for PSA by comparing this assay with the microparticle enzyme immunoassay for PSA (MEIA) on the AxSYM analyzer (Abbott Laboratories, Abbott Park, IL) and a Hybritech Tandem R assay for PSA. The new chemiluminescent assay is recently available from Bayer Diagnostics (Tarrytown, NY) and can be run using the ACS: 180 Plus analyzer. Precision of the new chemiluminescent assay was evaluated using commercially available controls (Bayer Diagnostics). The within-run and total CVs were 6.4 and 8.7% for the low control (mean: 0.43 microg/L), 1.6 and 5.2% for the next level control (mean:1.94 mg/L), 4.3 and 4.9% for the medium control (mean: 2.10 mg/L), 1.2 and 3.9% for the high control 1 (mean: 11.52 mg/L), and finally 3.2 and 6.9% for the high control 2 (mean: 21.52 mg/L). The spike recovery varied from 94.2 to 109.6% for five different specimens we studied. We also observed excellent dilution recoveries. For example, in the specimen supplemented with 3.02 mg/L of PSA, the dilution recoveries were 102. 1, 104.7, and 103.7% for 1:2, 1:4, and 1:8 dilutions, respectively. We analyzed 113 serum specimens from patients with various concentrations of PSA (range 0.5 mg/L-2040 mg/L) using the new chemiluminescent assay and compared our results with the MEIA and Hybridtech (Tandem-R PSA) assays. Using x axis as the PSA concentrations obtained by the Tandem-R assay and the y axis as the PSA values obtained by the new chemiluminescent assay, we observed the following regression equations: y = 1.04 x -0.19 (r = 0.99, n = 112). One specimen with PSA concentrations of 2040 microg/L by the MEIA and 2156 microg/L by the chemiluminescent assay was not used for regression analysis. Similarly using x axis as the PSA concentrations obtained by the MEIA assay and y axis as the PSA concentrations obtained by the chemiluminescent assay, we observed the following regression equation: y = 0.88 + 0.02 (r = 0.99, n = 112). We conclude that the new chemiluminescent assay has excellent precision and the results compared well with the existing assays. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10906769      PMCID: PMC6808032          DOI: 10.1002/1098-2825(2000)14:4<164::aid-jcla5>3.0.co;2-m

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  9 in total

Review 1.  Prostate-specific antigen testing for early diagnosis of prostate cancer: formulation of guidelines.

Authors:  H B Carter; J D Pearson
Journal:  Urology       Date:  1999-11       Impact factor: 2.649

2.  Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared.

Authors:  D W Chan; D J Bruzek; J E Oesterling; R C Rock; P C Walsh
Journal:  Clin Chem       Date:  1987-10       Impact factor: 8.327

3.  Prognostic importance of prostate-specific antigen for monitoring patients with stages B2 to D1 prostate cancer.

Authors:  C S Killian; N Yang; L J Emrich; F P Vargas; M Kuriyama; M C Wang; N H Slack; L D Papsidero; G P Murphy; T M Chu
Journal:  Cancer Res       Date:  1985-02       Impact factor: 12.701

4.  Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate.

Authors:  T A Stamey; N Yang; A R Hay; J E McNeal; F S Freiha; E Redwine
Journal:  N Engl J Med       Date:  1987-10-08       Impact factor: 91.245

Review 5.  Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer.

Authors:  P H Lange; M K Brawer
Journal:  Urology       Date:  1989-06       Impact factor: 2.649

Review 6.  Prostate-specific antigen in management of prostatic carcinoma.

Authors:  M K Brawer; P H Lange
Journal:  Urology       Date:  1989-05       Impact factor: 2.649

7.  Prospective evaluation of prostate cancer detection by prostate-specific antigen-related parameters.

Authors:  S Egawa; K Suyama; R Takashima; H Mizoguchi; S Kuwao; S Baba
Journal:  Int J Urol       Date:  1999-10       Impact factor: 3.369

8.  The proteolytic activity of human prostate-specific antigen.

Authors:  Y Ban; M C Wang; K W Watt; R Loor; T M Chu
Journal:  Biochem Biophys Res Commun       Date:  1984-09-17       Impact factor: 3.575

9.  Purification of a human prostate specific antigen.

Authors:  M C Wang; L A Valenzuela; G P Murphy; T M Chu
Journal:  Invest Urol       Date:  1979-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.